Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1066 | Male Reproduction | ICEECE2012

Subcutaneous gonadotropin therapy for male infertility by hypogonadotropic hypogonadism

Moreno P. , Moreno M. Galvez , Exposito M. Alhambra , Sanchez I. Prior , Jimenez C. Munoz , Ortega R. Palomares , Lopez P. Benito

Objetive: Evaluate the efficacy of subcutaneous HCG with or without FSH in male infertility associated to hypogonadotropic hypogonadism (HH).Patients and methods: Descriptive study of patients with HH treated with HCG s.c. with or without FSH, for fertility objective (2004–2011). The Treatment was initiated with HCG 500 UI/72 h s.c., periodic monitoring of testosterone and semen analysis was realized, adjusting doses up to 2500 UI/72 h. If no answer...

ea0029p1139 | Neuroendocrinology | ICEECE2012

Pituitary incidentaloma: clinical presentation and endocrine evaluation in a Spanish population

Alhambra Exposito M. , Galvez Moreno M. , Tenorio Jimenez C. , Moreno Moreno P. , Benito Lopez P.

Introduction: The incidence of previously unrecognized lesions within the pituitary has been studied by MRI. The data suggest that up to 10% of people have clinically unsuspected pituitary tumors, the majority being<10 mm. Currently, little information is available about the prevalence of incidentally-discovered sellar masses.Objective: To perform a clinical audit on pituitary incidentalomas in order to establish an appropriate clinical approach to t...

ea0011p609 | Neuroendocrinology and behaviour | ECE2006

Effect of pegvisomant on glucose metabolism

Aznar S , Boix E , Revert P , Moreno O , López-Maciá A , Picó A

Aim: To quantify the effect of pegvisomant on glucose homeostasis, lipid profile and disease activity in acromegaly.Methods: 5 Patients with active acromegaly after surgery, radiotherapy and somatostatin analogs were included. Somatostatin analogs were withdrawn 6 weeks before starting pegvisomant and it was initially administered subcutaneously at doses of 10 mg daily. Doses were progressively increased every 3 to 4 weeks until IGF1 normalization. Gluco...

ea0029p580 | Diabetes | ICEECE2012

Association between educational level with glycemic and risk factor control in type 1 diabetes: results from DIACAM 1 study

Sastre J , Pines P , Moreno J , Quiroga I , Delagado M , Calderon D , Herranz S , Lozano J , Lopez J

Objective and aims: This study was designed to investigate the clinical characteristics of a representative group of type 1 diabetic (T1D) population in Castilla La Mancha, a region in central Spain. The aim of this report is to evaluate the relationship between the educational level and cardiometabolic risk in adult patients with T1D.Patients and methods: This is an observational, cross-sectional, prospective and multicentre study of 1465 patients who r...

ea0070aep653 | Pituitary and Neuroendocrinology | ECE2020

Characterization of pituitary adenomas by immunohistochemistry of pituitary-specific transcription factors and their correlation with hormonal subtypes

García-Martínez Araceli , Silva-Ortega Sandra , López-Muñoz Beatriz , Moreno-Pérez Óscar , Monjas Irene , Abarca Javier , Picó Antonio , Aranda Ignacio

Introduction: The immunohistochemical characterization of Pit-1, Tpit and SF-1 transcription factors allows the identification of the three adenohypophyseal cell lines and has been incorporated into the latest WHO classification of pituitary adenomas (PA). The aim of the present study was to quantify the protein expression of pituitary-specific transcription factors (TF) by immunohistochemistry (IHC) and to correlate these results with the identification based on hormonal prot...

ea0029p1825 | Thyroid cancer | ICEECE2012

Prognostic markers in Papillary Thyroid Cancer by immunohistochemistry

Castelblanco E. , Gallel P. , Martinez M. , Barrera L. , Capel I. , Moreno P. , Gimenez G. , Puig-Domingo M. , Bella R. , Porta M. , Halperin I. , Lopez S. , Orellana R. , Cameselle J. , Matias-Guiu X. , Mauricio D. , Robledo M. , Maravall J.

Papillary thyroid cancer (PTC) is the most common endocrine malignancy. Its management has not changed significantly in recent decades, and most patients receive the same treatment. Moreover, there are not alternative treatments for low response or aggressive neoplasias. The availability of reliable prognostic markers that would allow the PTC to be identified based on their aggressiveness at the time of diagnosis would derive in an individualized treatment. In a previous study...